Identification of GZD824 as an Orally Bioavailable Inhibitor That Targets Phosphorylated and Nonphosphorylated Breakpoint Cluster Region-Abelson (Bcr-Abl) Kinase and Overcomes Clinically Acquired Mutation-Induced Resistance against Imatinib | |
Wang, Deping; Feng, Yubing; Zhuang, Xiaoxi; Zhang, Fengxiang; Liu, Jianqi; Leng, Fang; Lang, Xingfen; Bai, Yang; She, Miaoqin; Tu, Zhengchao | |
刊名 | JOURNAL OF MEDICINAL CHEMISTRY |
2013 | |
卷号 | 56期号:3 |
ISSN号 | 0022-2623 |
学科主题 | Pharmacology & Pharmacy |
语种 | 英语 |
内容类型 | 期刊论文 |
源URL | [http://ir.foo.ac.cn/handle/2SETSVCV/274] |
专题 | 中国科学院广州生物医药与健康研究院 |
推荐引用方式 GB/T 7714 | Wang, Deping,Feng, Yubing,Zhuang, Xiaoxi,et al. Identification of GZD824 as an Orally Bioavailable Inhibitor That Targets Phosphorylated and Nonphosphorylated Breakpoint Cluster Region-Abelson (Bcr-Abl) Kinase and Overcomes Clinically Acquired Mutation-Induced Resistance against Imatinib[J]. JOURNAL OF MEDICINAL CHEMISTRY,2013,56(3). |
APA | Wang, Deping.,Feng, Yubing.,Zhuang, Xiaoxi.,Zhang, Fengxiang.,Liu, Jianqi.,...&Ren, Xiaomei.(2013).Identification of GZD824 as an Orally Bioavailable Inhibitor That Targets Phosphorylated and Nonphosphorylated Breakpoint Cluster Region-Abelson (Bcr-Abl) Kinase and Overcomes Clinically Acquired Mutation-Induced Resistance against Imatinib.JOURNAL OF MEDICINAL CHEMISTRY,56(3). |
MLA | Wang, Deping,et al."Identification of GZD824 as an Orally Bioavailable Inhibitor That Targets Phosphorylated and Nonphosphorylated Breakpoint Cluster Region-Abelson (Bcr-Abl) Kinase and Overcomes Clinically Acquired Mutation-Induced Resistance against Imatinib".JOURNAL OF MEDICINAL CHEMISTRY 56.3(2013). |
个性服务 |
查看访问统计 |
相关权益政策 |
暂无数据 |
收藏/分享 |
除非特别说明,本系统中所有内容都受版权保护,并保留所有权利。
修改评论